284 related articles for article (PubMed ID: 20972459)
1. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ.
Chan SW; Lim CJ; Huang C; Chong YF; Gunaratne HJ; Hogue KA; Blackstock WP; Harvey KF; Hong W
Oncogene; 2011 Feb; 30(5):600-10. PubMed ID: 20972459
[TBL] [Abstract][Full Text] [Related]
2. WW domain-binding protein 2: an adaptor protein closely linked to the development of breast cancer.
Chen S; Wang H; Huang YF; Li ML; Cheng JH; Hu P; Lu CH; Zhang Y; Liu N; Tzeng CM; Zhang ZM
Mol Cancer; 2017 Jul; 16(1):128. PubMed ID: 28724435
[TBL] [Abstract][Full Text] [Related]
3. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
[TBL] [Abstract][Full Text] [Related]
4. Biophysical analysis of binding of WW domains of the YAP2 transcriptional regulator to PPXY motifs within WBP1 and WBP2 adaptors.
McDonald CB; McIntosh SK; Mikles DC; Bhat V; Deegan BJ; Seldeen KL; Saeed AM; Buffa L; Sudol M; Nawaz Z; Farooq A
Biochemistry; 2011 Nov; 50(44):9616-27. PubMed ID: 21981024
[TBL] [Abstract][Full Text] [Related]
5. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.
He L; Pratt H; Gao M; Wei F; Weng Z; Struhl K
Elife; 2021 Aug; 10():. PubMed ID: 34463254
[TBL] [Abstract][Full Text] [Related]
6. WBP2 negatively regulates the Hippo pathway by competitively binding to WWC3 with LATS1 to promote non-small cell lung cancer progression.
Han Q; Rong X; Lin X; Zhang X; Fan C; Zhao H; Wang E
Cell Death Dis; 2021 Apr; 12(4):384. PubMed ID: 33837178
[TBL] [Abstract][Full Text] [Related]
7. Structural features and ligand binding properties of tandem WW domains from YAP and TAZ, nuclear effectors of the Hippo pathway.
Webb C; Upadhyay A; Giuntini F; Eggleston I; Furutani-Seiki M; Ishima R; Bagby S
Biochemistry; 2011 Apr; 50(16):3300-9. PubMed ID: 21417403
[TBL] [Abstract][Full Text] [Related]
8. Wnt Signaling Promotes Breast Cancer by Blocking ITCH-Mediated Degradation of YAP/TAZ Transcriptional Coactivator WBP2.
Lim SK; Lu SY; Kang SA; Tan HJ; Li Z; Adrian Wee ZN; Guan JS; Reddy Chichili VP; Sivaraman J; Putti T; Thike AA; Tan PH; Sudol M; Virshup DM; Chan SW; Hong W; Lim YP
Cancer Res; 2016 Nov; 76(21):6278-6289. PubMed ID: 27578003
[TBL] [Abstract][Full Text] [Related]
9. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
Zhang Z; Du J; Wang S; Shao L; Jin K; Li F; Wei B; Ding W; Fu P; van Dam H; Wang A; Jin J; Ding C; Yang B; Zheng M; Feng XH; Guan KL; Zhang L
Mol Cell; 2019 Jan; 73(1):7-21.e7. PubMed ID: 30472188
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
11. Biophysical studies and modelling indicate the binding preference of TAZ WW domain for LATS1 PPxY motif.
Verma A; Lin F; Tan YC; Hidayat MN; Jobichen C; Fan H; Sivaraman J
Biochem Biophys Res Commun; 2018 Jul; 502(3):307-312. PubMed ID: 29787761
[TBL] [Abstract][Full Text] [Related]
12. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
13. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus.
Komuro A; Nagai M; Navin NE; Sudol M
J Biol Chem; 2003 Aug; 278(35):33334-41. PubMed ID: 12807903
[TBL] [Abstract][Full Text] [Related]
14. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
15. Identification of Prolyl isomerase Pin1 as a novel positive regulator of YAP/TAZ in breast cancer cells.
Khanal P; Yeung B; Zhao Y; Yang X
Sci Rep; 2019 Apr; 9(1):6394. PubMed ID: 31015482
[TBL] [Abstract][Full Text] [Related]
16. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
17. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
[TBL] [Abstract][Full Text] [Related]
18. WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway.
Hum M; Tan HJ; Yang Y; Srivastava S; Teh M; Lim YP
FASEB J; 2021 Feb; 35(2):e21290. PubMed ID: 33475198
[TBL] [Abstract][Full Text] [Related]
19. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
20. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
